Internal Medicine, Hematology & Oncology · Wichita, KS
NPI
1528029147
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
3243 E Murdock St, Suite 300
Wichita, KS, 67208
Phone (316) 262-4467
Groups this clinician bills Medicare through
Medicare paid, 2024
$9.0M
475,168 services
Medicare patients, 2024
1,353
Average age 75
Drug cost, 2024
$6.3M
2,946 prescriptions
Company payments, 2025
$3,372
From 49 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nassim H Nabbout was code J9271 (injection, pembrolizumab, 1 mg), 43,300 times for 64 patients. In total Nassim H Nabbout billed 475,168 services in 235 codes, and Medicare paid $9.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 43,300 | 64 | $44.48 | $1.9M |
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 41,940 | 38 | $0.22 | $9,148 |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 33,750 | 34 | $0.87 | $29K |
| J9299 Injection, nivolumab, 1 mg | Office | 33,420 | 27 | $24.61 | $822K |
| J0185 Injection, aprepitant, 1 mg | Office | 31,590 | 109 | $1.32 | $42K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 23,440 | 30 | $2.33 | $55K |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 21,600 | 102 | $4.32 | $93K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 17,370 | 26 | $0.05 | $940 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 14,580 | 22 | $39.55 | $577K |
| J0897 Injection, denosumab, 1 mg | Office | 12,840 | 77 | $20.33 | $261K |
| J9267 Injection, paclitaxel, 1 mg | Office | 9,927 | 26 | $0.08 | $781 |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 6,864 | 40 | $20.88 | $143K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 6,630 | 11 | $0.26 | $1,738 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 5,838 | 221 | $0.09 | $520 |
| J9173 Injection, durvalumab, 10 mg | Office | 4,714 | 12 | $63.58 | $300K |
By year: 2022 $5.0M for 336,797 services; 2023 $6.3M for 424,823 services; 2024 $9.0M for 475,168 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,644 | 374 | $8.61 | $14K |
| 85027 Blood Count | 1,594 | 368 | $6.31 | $10K |
| 85007 Blood Count | 1,592 | 368 | $3.70 | $5,897 |
| 80053 Clinical Chemistry | 1,266 | 352 | $10.30 | $13K |
| 82378 Clinical Chemistry | 181 | 109 | $18.58 | $3,363 |
| 84443 Clinical Chemistry | 153 | 44 | $16.46 | $2,518 |
| 84439 Clinical Chemistry | 143 | 35 | $8.84 | $1,264 |
| 82728 Clinical Chemistry | 134 | 67 | $13.36 | $1,790 |
| 83540 Clinical Chemistry | 124 | 64 | $6.34 | $786 |
| 83550 Clinical Chemistry | 123 | 64 | $8.57 | $1,054 |
Medicare prescription drug claims, 2024
In 2024, the drug Nassim H Nabbout prescribed most often to Medicare patients was Anastrozole, with 459 prescriptions and refills. In total Nassim H Nabbout wrote 2,946 Medicare prescriptions that cost $6.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 459 | 868 | 93 | $4,961 |
| Acyclovir Generic | 199 | 287 | 39 | $2,305 |
| Prednisone Generic | 171 | 196 | 45 | $700 |
| Ondansetron Hcl Generic | 152 | 153 | 85 | $3,017 |
| Eliquis Apixaban | 140 | 156 | 27 | $88K |
| Xarelto Rivaroxaban | 107 | 123 | 17 | $69K |
| Potassium Chloride Generic | 102 | 120 | 30 | $1,270 |
| Allopurinol Generic | 81 | 110 | 22 | $316 |
| Dexamethasone Generic | 80 | 91 | 34 | $1,104 |
| Hydroxyurea Generic | 76 | 134 | 17 | $1,193 |
| Levofloxacin Generic | 76 | 76 | 39 | $343 |
| Letrozole Generic | 65 | 137 | 17 | $903 |
| Jakafi Ruxolitinib Phosphate | 65 | 65 | Under 11 | $965K |
| Gabapentin Generic | 64 | 84 | 15 | $669 |
| Anagrelide Hcl Generic | 51 | 59 | Under 11 | $1,648 |
Brand drugs: 641 claims; generic drugs: 2,305 claims; opioid claims: 83.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nassim H Nabbout $3,372 ($3,372 in general payments such as food, travel and fees) from 49 companies. The largest payer was Abbvie Inc. with $329.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 20 | $329 |
| Pfizer Inc. PFE | 24 | $265 |
| E.R. Squibb & Sons, L.L.C. BMY | 18 | $229 |
| Novartis Pharmaceuticals Corporation NVS | 12 | $229 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $198 |
| Daiichi Sankyo Inc. 4568.T | 7 | $155 |
| Intuitive Surgical, Inc. ISRG | 1 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 4 | $102 |
| GlaxoSmithKline, LLC. GSK | 4 | $94.84 |
| EMD Serono, Inc. MRK.DE | 5 | $94.34 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.